Consumption of food containing soy isoflavones does not appear to increase the risk of cancer recurrence or mortality among breast cancer survivors, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.
WEDNESDAY, April 6 (HealthDay News) -- Consumption of food containing soy isoflavones does not appear to increase the risk of cancer recurrence or mortality among breast cancer survivors, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.
Xiao Ou Shu, M.D., Ph.D., of Vanderbilt University in Nashville, Tenn., and colleagues assessed soy isoflavone consumption among 16,048 women with invasive breast cancer an average of 13 months after diagnosis using food frequency questionnaires for a group of soy isoflavones in three cohorts and on tofu and soy milk consumption in one cohort.
Although the findings were not statistically significant, breast cancer survivors who consumed more than 23 mg per day of soy isoflavones experienced a 9 percent reduced risk of mortality and a 15 percent reduced risk for recurrence compared to those who consumed no more than 0.48 mg per day of soy isoflavones.
"Our results indicate it may be beneficial for women to include soy food as part of a healthy diet, even if they have had breast cancer," Shu said in a statement. "This can't be directly generalized to soy supplements, however, as supplements may differ from soy foods in both the type and amount of isoflavones."
Abstract No. 4665More Information
Related Content
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
Hormone replacement therapy does not increase breast cancer recurrence, mortality in survivors
July 20th 2022An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.
Read More